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Background: Birth asphyxia, estimated to account for a million neonatal deaths annually, can cause 34 
a wide variety of neurodevelopmental impairments. There is a need to develop new, swift methods to 35 
identify those neonates who would benefit from neuroprotective treatments such as hypothermia.  36 
Objectives: To examine the utility of cord serum copeptin, a stable byproduct of arginine vasopressin 37 
release, as a biomarker of birth asphyxia based on a comparison with two biomarkers of hypoxia and 38 
brain trauma, erythropoietin and S100B.  39 
Methods: The study population consisted of 140 singleton, term neonates; 113 controls and 27 with 40 
birth asphyxia (two/three criteria met: umbilical artery pH <7.10, base excess <-12 mmol/l, and 5-41 
minute Apgar score <7). All deliveries were planned vaginal, but 51 neonates were born by 42 
emergency cesarean section. Copeptin, S100B, and erythropoietin levels in umbilical artery samples 43 
were measured by immunoassays.  44 
Results: Copeptin correlated in the entire study population more strongly with umbilical artery base 45 
excess than S100B and erythropoietin, and only copeptin correlated with arterial pH. Furthermore, 46 
only copeptin levels were significantly higher in cases of birth asphyxia, and in vaginally born 47 
neonates they were found to increase as a function of labor duration. Copeptin was elevated in 48 
neonates born via vacuum extraction, whereas erythropoietin levels showed a slight increase after 49 
emergency cesarean section.  50 
Conclusions: In this study population, S100B and erythropoietin were not valid biomarkers of birth 51 
asphyxia. In contrast, our work suggests that copeptin has high potential to become a routinely used 52 




Introduction  54 
Birth asphyxia is a severe clinical problem globally, which has been estimated to account for a million 55 
of neonatal deaths annually [1]. The neurodevelopmental impairments in individuals who develop 56 
neonatal hypoxic-ischemic encephalopathy (HIE) range from minor cognitive problems and 57 
sensorimotor defects to cerebral palsy [1, 2]. Methods for identifying those neonates who would 58 
benefit from neuroprotective treatments such as therapeutic hypothermia is a major challenge because 59 
of the restricted time window of only a few hours for decision making. The increasing risk of HIE 60 
associated with enhanced acidemia has been well established.  The Apgar scores at 5 minutes are 61 
known to correlate with the risk of neurological disability [3]. However, the sensitivity and specificity 62 
of arterial cord blood pH values and Apgar scores with regard to outcome following HIE are low [2]. 63 
Thus, reliable biomarkers for predicting outcome after birth asphyxia are urgently needed.   64 
 65 
A number of studies on blood-borne protein biomarkers in neonates have been published in recent 66 
years [4-6]. Among these, erythropoietin (EPO) is a biomarker of chronic hypoxia [7], and high levels 67 
of umbilical plasma EPO at birth are associated with an increased risk for adverse outcome [8]. S100B 68 
is considered as a biomarker of brain cell damage [9], and its levels are known to rise at the early 69 
phase of acute asphyxia [6]. In the present study, we examine the utility of cord serum copeptin, a 70 
byproduct of arginine vasopressin (AVP) release, as a biomarker of birth asphyxia based on a 71 
comparison with EPO and S100B. The rationale of this approach lies in the fact that a massive surge 72 
of AVP release takes place during normal vaginal birth in response to activation of the fetal 73 
hypothalamic–pituitary–adrenal (HPA) axis, which is further accentuated by various kinds of stress 74 
factors such as infections, intra-uterine growth restriction, and acidosis/birth asphyxia  [4, 5, 10, 11]. 75 
In contrast to AVP, copeptin is biochemically stable with a much longer half-life, and it is released 76 
in an equimolar ratio to AVP, making it an ideal surrogate for AVP measurements [11, 12]. One of 77 
the practical advantages of copeptin is that it is widely used as a biomarker of various 78 
pathophysiological states like lower respiratory tract infections, septic shock and stroke in emergency 79 
departments [13]. 80 
 81 
Methods 82 




The serum samples for this retrospective study were collected in the Department of Obstetrics and 84 
Gynecology, Helsinki University Hospital, Finland between May 2012 and April 2013. The study, 85 
approved by the local Ethics Committee of the Department of Obstetrics and Gynecology, Helsinki 86 
University Hospital, Finland (105/13/13/03/2012), consisted of 151 singleton births at or beyond 87 
37+0 gestational weeks. Umbilical artery blood samples were collected immediately after birth from 88 
72 neonates with suspected asphyxia, based on a 1-minute Apgar score <4. The 1-minute Apgar score 89 
was used only for patient recruitment, to allow midwives to identify neonates suspected of having 90 
suffered from birth asphyxia. Umbilical artery cord blood samples from 79 control neonates with a 91 
1-minute Apgar score ≥4 were collected during the five-day work week. Pregnancies complicated by 92 
maternal type 1 diabetes (n=1), preeclampsia (n=3), fetal growth restriction (n=4) and Rh 93 
immunization (n=1) were excluded. In addition, one neonate was excluded because of chromosomal 94 
anomaly and one had mitochondrial disease, leaving a total of 140 neonates for the final analysis. The 95 
neonates were divided into two groups, asphyxia and control, for data analysis. The neonate was 96 
considered to fulfill the diagnostic criteria for birth asphyxia if two of three criteria were met: 97 
umbilical artery pH <7.1, umbilical artery base excess <-12 mmol/l, and a 5-minute Apgar score <7 98 
[14, 15].    99 
 100 
Gestational age was defined by fetal crown-rump length measurement at the first trimester ultrasound 101 
screening. Deliveries were all planned vaginal. Indications for emergency cesarean sections (ECS) 102 
were: fetal distress (n=29), labor dystocia (n=10), prolonged second stage of delivery (n=2), 103 
chorionamnionitis (n=1), fetal malpresentation (n=3), unsuccessful vacuum extraction (n=4), and 104 
umbilical cord prolapse (n=2). Data on maternal pregnancy characteristics and short-term perinatal 105 
outcome were collected from the hospital charts (table 1). Birth weight z-score was defined according 106 
to the Finnish population standardized for sex and gestational age [16].  107 
 108 
Blood samples from the umbilical artery were used for measurements of pH, base excess (BE), pO2 109 
and pCO2 (Radiometer ABL800 Flex blood gas analyzer, Copenhagen, Denmark). Serum samples 110 
from the umbilical artery were used for biomarker measurements. 111 
 112 
Copeptin measurements 113 
We used a sandwich enzyme-linked immunosorbent assay (ELISA, methodological details in the 114 




the CV from eight duplicate samples run on two plates on two separate days. Fifteen serum samples 116 
were analyzed with both the ELISA and the BRAHMS copeptin Kryptor assay used in previous 117 
publications [4, 5], and a highly significant linear correlation (Pearson r = 0.9793, p < 0.0001) was 118 
found, covering the full range of values obtained using the Kryptor, 6.0 to 4637 pmol/l (median 381.2 119 
pmol/l). This excellent linear correlation, with an R2 of 0.9591 indicating a congruence of 96 % 120 
between the two methods, was used to convert the copeptin concentrations obtained with the ELISA 121 
to Kryptor concentrations. This allows for a direct comparison of our data with the already published 122 
copeptin results in neonates.  123 
 124 
S100B measurements 125 
Serum S100B was measured with electrochemiluminometric immunoassay using Modular e170 126 
analyzer (Roche Diagnostics). The detection range for the S100B assay is 0.005 μg/l and functional 127 
sensitivity less than 0.02 μg/l. The intra-assay coefficient of variation (CV) was less than 2.1 % and 128 
inter-assay variation better than 6.4 %.  129 
 130 
EPO measurements 131 
EPO was measured using a solid-phase chemiluminescent enzyme immunometric assay Immulite 132 
2000 XPI analyser (Siemens Healthcare Diagnostics). The intra-assay CV was 3.6-6.8 %, while the 133 
total CV was 6.4-10.3 %. Detection limit was 1.0 IU/l, and functional sensitivity (CV 20 %) was 1.5 134 
IU/l.  135 
 136 
Statistical analysis 137 
All three biomarkers were measured from each of the 140 samples included in this study. The 138 
following statistical analyses were performed with GraphPad Prism 6 or SPSS 22. Prior to calculating 139 
correlations and significances, statistical outliers (p < 0.01) for copeptin and S100B (n=1 for each) 140 
were excluded from the study population. Correlations between the pH, BE, S100B, EPO and 141 
copeptin values from all remaining samples were calculated with the Spearman correlation 142 
coefficient. Copeptin, S100B and EPO values between the study groups were compared using the 143 
Mann-Whitney U test or the Kruskall-Wallis test, and a receiver operating characteristic (ROC)-curve 144 
was drawn to determine the diagnostic accuracy of copeptin to birth asphyxia. The Chi-squared test 145 





Results  148 
Maternal and fetal/delivery characteristics 149 
The maternal and fetal/delivery characteristics are shown in table 1. There were no statistically 150 
significant differences in any of the maternal or delivery characteristics between the two study groups. 151 
 152 
Dependence of biomarker levels on umbilical artery pH and BE 153 
The neonates’ median pH, BE, pO2 and pCO2 values, which are routinely measured from umbilical 154 
arterial cord blood at birth, are shown in table 1. The dependence of the three biomarkers on the blood 155 
acid-base parameters are given in figure 1. Only copeptin levels showed a significant correlation with 156 
umbilical artery pH (r = -0.6219, p < 0.0001, fig. 1a). All three biomarkers correlated with umbilical 157 
artery BE (fig. 1d-f), with copeptin showing by far the highest correlation coefficient (r = -0.6372, p 158 
< 0.0001).  159 
 160 
Biomarker levels and asphyxia 161 
Twenty-seven neonates in the study population belonged to the birth asphyxia group (see Methods 162 
for present criteria). Copeptin levels were significantly higher among the neonates in the birth 163 
asphyxia group compared to unaffected controls (mean 2450 pmol/l vs 1226 pmol/l, p < 0.0001, fig. 164 
2c), whereas no differences in S100B (fig. 2a) or EPO (fig. 2b) levels were found. ROC-curve analysis 165 
showed that copeptin concentrations discriminated with moderate accuracy between asphyxia, as 166 
defined in this study, and controls: the area under the curve was 0.76 (95%-CI 0.69-0.86, fig. 2d). A 167 
cut-off of 1522 pmol/l had a sensitivity of 77 % and a specificity of 70%.  168 
 169 
Biomarker levels and delivery mode 170 
All 140 deliveries were planned vaginal, but 51 neonates were ultimately born by ECS. Of the 89 171 
vaginal deliveries, 33 were assisted with vacuum extraction. There were no differences in the delivery 172 
mode between the asphyxia and control study groups (table 1). Copeptin levels were higher among 173 
the neonates born via vacuum extraction as compared to ECS (mean 2021 pmol/l vs 1190 pmol/l, p 174 
= 0.003, fig. 3a) or normal vaginal delivery, although the latter difference did not reach statistical 175 
significance (mean 2021 pmol/l vs 1362 pmol/l, p = 0.0522, fig. 3a). No differences in S100B levels 176 




ECS compared to normal vaginal delivery or vacuum extraction (means 713.7 U/l, 78.41 U/l, and 178 
61.15 U/l, respectively; p = 0.0002 and p = 0.001, fig. 3c), which might reflect prenatal conditions 179 
[7]. 180 
 181 
Biomarker levels in relation to other variables 182 
S100B levels were higher in male neonates (p = 0.0378), but copeptin and EPO levels did not differ 183 
based on the sex of the neonate. All biomarkers showed a correlation with the 5-minute Apgar score, 184 
and copeptin and S100B correlated also with the 10-minute Apgar score (table 2). Copeptin and 185 
S100B levels did not correlate with gestational age at birth, whereas EPO levels did (r = 0.4513, p < 186 
0.0001). Only copeptin levels correlated significantly with birth weight (r = -0.1713, p = 0.0438). 187 
Among the 89 neonates born vaginally, copeptin levels increased as a function of the total duration 188 
of labor (r = 0.3267, p = 0.0019) and the duration of the second stage of labor (r = 0.2787, p = 0.0086; 189 
table 2). EPO and S100B levels did not correlate with either of these variables.  190 
 191 
Discussion 192 
A wide spectrum of adaptive processes in respiratory, cardiovascular, and metabolic functions are 193 
triggered at birth [4, 10]. Changes in biomarker concentrations during birth reflect, at least in part, 194 
physiological fetal adaptive reactions, such as enhanced activation of the HPA-axis (see below), in 195 
response to normal or complicated delivery. Distinct biomarkers have different profiles during fetal 196 
and neonatal asphyxia [4, 7, 18]. The S100B level in plasma has been shown to rise at the early phase 197 
of acute asphyxia [6, 18] and significantly higher S100B levels have been reported in asphyxiated 198 
term neonates with intraventricular hemorrhage (IVH) or with HIE, compared to asphyxiated 199 
neonates without IVH/HIE or to apparently healthy neonates [19]. EPO is a biomarker of chronic 200 
hypoxia, and increased levels can be detected in fetal plasma and amniotic fluid in various 201 
pathological pregnancies [7]. An association of high EPO levels during pregnancy and adverse acute 202 
neonatal outcome, such as decreased umbilical cord pH, pO2 and BE, and increased intensive care 203 
unit admission, has also been reported [7, 20]. Furthermore, high levels of umbilical plasma EPO at 204 
birth are associated with an increased risk for death or abnormal neurological outcome at two years 205 





There are many a priori reasons why copeptin might turn out to be a highly useful biomarker of birth 208 
asphyxia, and a number of previous observations point in this direction [4, 5, 21]. During birth, the 209 
HPA axis shows massive activation, which results in the release of AVP, and this response is further 210 
enhanced by various types of stressors. Since AVP is highly unstable with a short half-life of 4-20 211 
minutes [22], assays of this hypothalamic hormone itself are not suitable for clinical use. However, 212 
AVP is derived from a larger precursor peptide which contains copeptin, a stable C-terminal fragment 213 
with 39 amino acids. Copeptin is released in an equimolar ratio to AVP [23]. In line with the 214 
underlying HPA-based mechanisms, copeptin levels in cord blood increase in different stress 215 
situations, such as infections and hypoxia, both in term and preterm pregnancies [4, 5, 21]. High 216 
copeptin levels at birth are related to acute adverse neonatal outcomes such as IVH [21]. 217 
 218 
The single most important criterion for diagnosis of birth asphyxia is profound metabolic acidosis 219 
[14, 15]. Notably, copeptin levels increase along with decreasing umbilical cord blood pH and BE 220 
during normal birth [4], and they are even higher following birth asphyxia [5]. This means that the 221 
dynamics of enhanced copeptin plasma concentrations cover a wide range of levels of acidemia from 222 
normal to severely abnormal, i.e. those prevailing in birth asphyxia. 223 
 224 
In line with the above considerations and data, we demonstrate here that copeptin levels are highly 225 
correlated with both arterial cord blood pH and BE (fig. 1). The strong and highly significant 226 
dependence of high copeptin levels on negative BE shown presently is of particular interest. In 227 
excellent agreement with the above data, copeptin levels turned out to be significantly higher in 228 
asphyxiated neonates vs controls in the present study. The sensitivity and specificity parameters in 229 
the ROC analysis were not as high as previously shown [5], which is attributable to the present 230 
inclusion criteria of the control group based on a 1-minute Apgar score of 4 or higher. In contrast, no 231 
difference was seen in S100B and EPO levels (fig. 2), most likely because of the relatively mild 232 
asphyxia criteria in the present work.   233 
 234 
A further important finding in the present study is that copeptin levels increased as a function of the 235 
total duration of labor and on the duration of the second stage of labor, while EPO and S100B levels 236 
did not correlate with either variable. This result with copeptin is most likely explained by very recent 237 




on the fetus) are sufficient to trigger detectable AVP/copeptin [24]. Given the cumulative nature of 239 
the copeptin levels with a half-life of 30 minutes [25], the above dependence on labor duration is 240 
readily explained. Thus, future work on sequential measurements of copeptin may turn out to be 241 
valuable in enhancing the prognostic power of this biomarker.  242 
 243 
It has been previously shown that significantly higher copeptin concentrations are observed after 244 
vaginal delivery compared to delivery by primary cesarean section [4]. In the present study, the 245 
patient cohort included only neonates born by ECS preceded by periods of labor contractions with 246 
variable duration. Thus, it is not surprising that no significant difference in copeptin levels was 247 
observed between neonates born vaginally or via ECS. However, copeptin levels were higher after 248 
vaginal delivery assisted by vacuum extraction when compared to copeptin levels after ECS or normal 249 
vaginal delivery, as reported before [4].  250 
 251 
To summarize, our study indicates that copeptin has a high potential to become a routine biomarker 252 
for neonatal distress and asphyxia. From a (patho)physiological point of view, its advantages are 253 
based on the key role of AVP in the adaptations of the fetus to birth.  From a practical point of view, 254 
it is of much importance that serum copeptin is widely used as a biomarker in adults in emergency 255 
departments [13], and therefore this approach can be readily extended to neonatal intensive care units. 256 
Future studies are needed to determine whether copeptin concentrations at birth correlate with the 257 
severity of HIE, and, more importantly, with long-term neurological outcome following birth 258 
asphyxia.  259 
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Figure legends 330 
 331 
Fig. 1 Dependence of copeptin (a, d), S100B (b, e) and EPO levels (c, f) on pH (a-c) and base excess 332 
(BE; d-f). P - and r - values for each pair are shown in the respective panels, regression lines were 333 
drawn when the correlation was significant. 334 
 335 
Fig. 2 Comparisons between the birth asphyxia and control groups. There were no significant 336 
differences in S100B (a) or EPO (b) levels between the groups. Copeptin (c) levels were significantly 337 
higher in the asphyxia group compared to the control group. The medians and p-values of Mann-338 
Whitney U-test are shown (a-c). (d) ROC-curve for cord serum copeptin concentrations in relation to 339 
birth asphyxia. The dotted lines indicate the optimal discriminative cut-off of 1522 pmol/l, resulting 340 
in a sensitivity of 77 % and a specificity of 70 %.  341 
 342 
Fig. 3 Comparisons between biomarkers and delivery mode. Copeptin (a) levels were significantly 343 
higher in neonates born via vacuum extraction compared to emergency cesarean section, whereas no 344 
differences in S100B (b) levels were found between groups. EPO (c) levels were significantly higher 345 
in neonates born via emergency cesarean section compared to the two other groups. The medians are 346 
shown in each panel, and p - values of Kruskal-Wallis test are shown when the difference was 347 







Table 1. Maternal and fetal/delivery characteristics of the study groups 
p
Maternal characteristics
Maternal age, years (mean) 30.9 SD (5.9) 31.1 SD (5.5) 0.815
Primiparity 15 (55.6) 62 (54.9) 1.000
In vitro  fertilization 2 (7.4) 5 (4.4) 0.620
Smoking 4 (14.8) 9 (8.0) 0.277




) 2 (7.4) 17 (15.0) 0.530
Gestational diabetes 4 (14.8) 14 (12.4) 0.751
Chronic hypertension 1 (3.7) 3 (2.7) 0.580
Fetal/delivery characteristics
Spontaneous vaginal delivery 7 (25.9) 49 (43.4) 0.257
Vacuum extraction 9 (33.3) 24 (21.2) 0.309
Emergency cesarean section 11 (40.7) 40 (35.4) 0.727
Gestational weeks at birth 41.1 (40.0 - 41.6) 40.7 (39.7 - 41.7) 0.372
Post-term births (≥H42
+0
) 5 (18.5) 22 (19.5) 1.000
Male 17 (63.0) 66 (58.4) 0.828
Birth weight (g) 3520 (3260 - 3945) 3656 (3282 - 3991) 0.499
Relative birth weight (SD) -0.13 (-1.02 - 0.62) 0.02 (-0.67 - 0.81) 0.385
5 min Apgar score 6 (4-7) 8 (6-9) <0.0001
10 min Apgar score 8 (6-9) 9 (8-9.5) 0.0009
Umbilical artery pH 7.03 (6.97 - 7.08) 7.21 (7.14 - 7.30) <0.0001
Umbilical artery base excess -12.7 (-14.4 - -11.1) -5.80 (-7.85 - -2.85) <0.0001
Umbilical artery pO2 (kPa) 1.9 (1.1 - 2.8) 2.4 (1.7 - 3.3) 0.029
Umbilical artery pCO2 (kPa) 10.1 (9.2 - 12.7) 7.8 (6.7 - 9.2) <0.0001
Umbilical serum erythropoietin (U/l) 71.7 (22.2 - 116.0) 46.1 (22.2 - 124.5) 0.683
Umbilical serum S100B (µg/l) 0.33 (0.19 - 0.63) 0.31 (0.24 - 0.45) 0.712
Umbilical serum copeptin (pmol/l) 2279 (1476-3144) 973.7 (320.9-1961) <0.0001
Median (interquartile range) or number (percentage) are shown 
Asphyxia (n = 27) Control (n = 113)
Table 2. Biomarker correlations to other variables
n r p n r p n r p
5 min Apgar score 139 -0.2998 0.0004* 139 -0.2041 0.0159* 140 -0.2914 0.0005*
10 min Apgar score 139 -0.1678 0.0484* 139 -0.2048 0.0156* 140 -0.1380 0.1040
Gestational age 139 0.0644 0.4510 139 -0.0018 0.9836 140 0.4513 <0.0001*
Birth weight 139 -0.1713 0.0438* 139 -0.0235 0.7838 140 -0.0367 0.6672
Total labor duration 88 0.3267 0.0019* 89 0.1247 0.2444 89 0.0656 0.5414
Second stage labor duration 88 0.2787 0.0086* 89 0.1038 0.3332 89 0.0162 0.8802
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